US 11,730,775 B2
Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereof
Gregory McKenzie, Arlington, MA (US); Mary-Jane Lombardo McKenzie, Arlington, MA (US); David N. Cook, Brooklyn, NY (US); Marin Vulic, Boston, MA (US); Geoffrey Von Maltzahn, Boston, MA (US); Brian Goodman, Boston, MA (US); John Grant Aunins, Doylestown, PA (US); Matthew R. Henn, Somerville, MA (US); David Arthur Berry, Brookline, MA (US); and Jonathan Winkler, Boston, MA (US)
Assigned to Seres Therapeutics, Inc., Cambridge, MA (US)
Filed by Seres Therapeutics, Inc., Cambridge, MA (US)
Filed on Apr. 5, 2021, as Appl. No. 17/222,778.
Application 14/313,828 is a division of application No. 14/197,044, filed on Mar. 4, 2014, granted, now 9,011,834, issued on Apr. 21, 2015.
Application 17/222,778 is a continuation of application No. 16/054,864, filed on Aug. 3, 2018, granted, now 10,967,011.
Application 16/054,864 is a continuation of application No. 15/847,623, filed on Dec. 19, 2017, granted, now 10,064,901, issued on Sep. 4, 2018.
Application 15/847,623 is a continuation of application No. 15/415,745, filed on Jan. 25, 2017, granted, now 9,855,303, issued on Jan. 2, 2018.
Application 15/415,745 is a continuation of application No. 14/884,655, filed on Oct. 15, 2015, granted, now 9,585,921, issued on Mar. 7, 2017.
Application 14/884,655 is a continuation of application No. 14/313,828, filed on Jun. 24, 2014, granted, now 9,180,147, issued on Nov. 10, 2015.
Application 14/197,044 is a continuation of application No. PCT/US2014/014745, filed on Feb. 4, 2014.
Claims priority of provisional application 61/926,918, filed on Jan. 13, 2014.
Claims priority of provisional application 61/760,606, filed on Feb. 4, 2013.
Claims priority of provisional application 61/760,585, filed on Feb. 4, 2013.
Claims priority of provisional application 61/760,584, filed on Feb. 4, 2013.
Claims priority of provisional application 61/760,574, filed on Feb. 4, 2013.
Prior Publication US 2021/0244774 A1, Aug. 12, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A01N 63/00 (2020.01); A61K 35/741 (2015.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61K 9/48 (2006.01); C12N 1/20 (2006.01); A61K 35/74 (2015.01); A61K 35/742 (2015.01); A61K 35/744 (2015.01); A61K 35/745 (2015.01); A61K 35/747 (2015.01); A61K 35/37 (2015.01)
CPC A61K 35/741 (2013.01) [A61K 9/0053 (2013.01); A61K 9/48 (2013.01); A61K 9/4816 (2013.01); A61K 35/37 (2013.01); A61K 35/74 (2013.01); A61K 35/742 (2013.01); A61K 35/744 (2013.01); A61K 35/745 (2013.01); A61K 35/747 (2013.01); A61K 45/06 (2013.01); C12N 1/20 (2013.01); Y02A 50/30 (2018.01)] 32 Claims
 
1. A method of treating Clostridium difficile infection (CDI) or a symptom thereof in a subject in need thereof, comprising administering a therapeutic composition to the subject in an amount effective to treat the CDI or a symptom thereof,
wherein the therapeutic composition is formulated for oral administration, and comprises:
a purified population of bacteria, and
a capsule; and
wherein the purified population of bacteria consists of spore-forming bacteria in the form of spores.